Xenetic Biosciences, Inc. SEC filings XBIO
Xenetic Biosciences, Inc. has 484 filings in SEC EDGAR's recent list, going back to Nov 21, 2011. Its latest annual report, Form 10-K, was filed on Mar 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 23, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Oct 14, 2025 | — |
| 424B5 | Prospectus supplement | Oct 10, 2025 | — |
| S-3 | Shelf registration | Oct 21, 2024 | — |
| S-8 | Employee stock plan registration | Dec 30, 2021 | — |
| 424B5 | Prospectus supplement | Nov 19, 2021 | — |
| S-3/A | Amendment to form s-3 | Oct 20, 2021 | — |
| S-3 | Shelf registration | Oct 12, 2021 | — |
| S-3 | Shelf registration | Aug 13, 2021 | — |
| 424B5 | Prospectus supplement | Dec 11, 2020 | — |
| S-8 | Employee stock plan registration | Apr 1, 2020 | — |
| S-3 | Shelf registration | Sep 13, 2019 | — |
| 424B5 | Prospectus supplement | Jul 19, 2019 | — |
| S-1/A | Amended registration statement | Jul 12, 2019 | — |
| S-1/A | Amended registration statement | Jul 5, 2019 | — |
| S-1/A | Amended registration statement | Jul 2, 2019 | — |
| S-1/A | Amended registration statement | Jun 24, 2019 | — |
| S-1/A | Amended registration statement | May 24, 2019 | — |
| 424B3 | Prospectus | May 22, 2019 | — |
| S-4/A | Form s-4 amendment | May 20, 2019 | — |
| S-1 | Registration statement | May 15, 2019 | — |
| S-4/A | Amended registration statement | May 13, 2019 | — |
| S-4 | Registration for a merger or exchange | Mar 29, 2019 | — |
| 424B5 | Prospectus supplement | Mar 7, 2019 | — |
| S-3 | Shelf registration | Sep 27, 2018 | — |
| S-8 | Employee stock plan registration | Dec 22, 2017 | — |
| S-8 | Employee stock plan registration | May 16, 2017 | — |
| 424B4 | Prospectus | Nov 3, 2016 | — |
| S-1/A | Amended registration statement | Oct 31, 2016 | — |
| S-1/A | Amended registration statement | Oct 27, 2016 | — |
| S-1/A | Amended registration statement | Oct 27, 2016 | — |
| S-1/A | Amended registration statement | Oct 21, 2016 | — |
| S-1/A | Amended registration statement | Oct 11, 2016 | — |
| S-1/A | Amended registration statement | Sep 23, 2016 | — |
| S-1/A | Amended registration statement | Jul 14, 2016 | — |
| S-1/A | Amended registration statement | Jul 8, 2016 | — |
| S-1/A | Amended registration statement | Jun 24, 2016 | — |
| S-1 | Registration statement | May 9, 2016 | — |
| 424B3 | Prospectus | Mar 23, 2012 | — |
| S-1/A | Amended registration statement | Mar 2, 2012 | — |
| S-1/A | Amended registration statement | Feb 3, 2012 | — |
| S-1/A | Amended registration statement | Jan 11, 2012 | — |
| S-1 | Registration statement | Nov 21, 2011 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534525
- Former names
- General Sales & Leasing, Inc. (until Jan 10, 2014); GENERAL AIRCRAFT INC. (until Feb 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.